1	Research Letter: Incidence of SARS-CoV-2 infection among unvaccinated US adults during the Omicro			
2	wave			
3				
4	Jennifer L. Alejo, MD¹, Teresa PY Chiang, MD, MPH¹, Jonathan Mitchell, MBBS¹, Aura T. Abedon, BS¹,			
5	Alexa A. Jefferis, BS ¹ , William Werbel, MD ¹ , Allan B. Massie PhD, MHS ² , Martin A. Makary MD, MPH* ¹ ,			
6	Dorry L. Segev, MD PhD*2			
7	*Senior authors contributed equally			
8				
9	(1) Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.			
10	(2) Department of Surgery, NYU Grossman School of Medicine, New York, NY.			
11				
12 13 14				
15	Contact Information:			
16	Dorry Segev, M.D., Ph.D.			
17	Professor of Surgery			
18	NYU Grossman School of Medicine			
19	dorry@nyulangone.org			
20				

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

Author Contributions: Dr. Alejo had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and Design: Alejo, Chiang, Mitchell, Werbel, Massie, Makary, Segev. Acquisition, analysis, interpretation of data: All authors. Drafting of the manuscript: All authors. Critical revision of the manuscript: Alejo, Chiang, Mitchell, Werbel, Massie, Makary, Segev. Statistical analysis: Alejo, Chiang, Massie, Segev. Obtained funding: Segev. Administrative, technical, or material support: All authors. Supervision: Massie, Makary, Segev. Conflict of Interest: DL Segev has the following financial disclosures: consulting and speaking honoraria from Sanofi, Novartis, CLS Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, Thermo Fisher Scientific, Astra Zeneca, and Regeneron. The remaining authors of this manuscript have no financial disclosures or conflicts of interest to disclose. Funding/Support: This work was supported by charitable donations from the Ben-Dov family. These authors received salary support from the following grants: T32DK007713 (Dr. Alejo), The ASTS Jonathan P. Fryer Resident Scientist Scholarship (Dr. Mitchell). Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication.

Acknowledgement: We acknowledge the following individuals for their assistance with this study, none of whom were compensated for their contributions: Jake D. Kim, BS, and Carolyn N. Sidoti, BS, for data collection and study coordination (Department of Surgery, Johns Hopkins School of Medicine); Daniel S. Warren, PhD (Department of Surgery, Johns Hopkins School of Medicine), Amy Chang, MD, (Department of Surgery, Johns Hopkins School of Medicine) and Macey L. Levan, JD, PhD (Departments of Acute and Chronic Care, Johns Hopkins School of Nursing, and Surgery, Johns Hopkins School of Medicine) for administrative and scientific support.

Abstract

As of 4/20/2022, approximately 23% of the eligible US population was unvaccinated. We studied COVID-19 infections during the Omicron (B.1.1.529) wave in unvaccinated US adults, stratified by pre-Omicron antibody levels. Anti-spike serologic testing was performed prior to the Omicron wave in the United States (9/23/21-11/5/21) and participants were surveilled to determine incident COVID-19. Only 12% of those who entered the wave with antibodies reported a test-confirmed COVID-19 infection, compared to 35% of those without antibodies prior to the Omicron wave. Effectiveness of these anti-RBD antibodies in this unvaccinated population was 67%. Among people with antibodies, titer did not appear to be associated with risk of test-confirmed Omicron infection.

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

As of 4/20/2022, approximately 23% of the eligible US population has not received at least one SARS-CoV-2-vaccine dose.[1] We recently reported that 99% of unvaccinated US adults who had a testconfirmed SARS-CoV-2 infection had detectable anti-RBD antibodies up to 20 months after their positive COVID-19 test.[2] However, whether these antibodies can be used as a clinical marker of protection against new variants is undescribed. To better understand protective correlates, we studied COVID-19 infections during the Omicron (B.1.1.529) wave in unvaccinated US adults, stratified by pre-Omicron antibody levels. Methods Self-described healthy adults who reported never receiving a SARS-CoV-2 vaccine were recruited for this national cohort study between (9/11/2021-10/8/2021).[2] Anti-spike serologic testing was performed prior to the Omicron wave (9/23/21-11/5/21), and categories of antibody titers were created based on reported associations with neutralization.[3-4] Participants completed a follow-up questionnaire (1/19/2022-2/7/2022) about COVID-19 test status and symptoms (since 12/1/2021): tested positive for COVID-19, suspected COVID-19 but never tested positive, or no suspected infection or positive test, and classified symptoms as severe, moderate, mild, or none. Population characteristics were compared using Fisher's exact test for categorical variables and Wilcoxon rank-sum test for continuous variables. All analyses were performed using Stata 17.0/SE. The study was approved by the Johns Hopkins institutional review board. Participants provided informed electronic consent. Results

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

Discussion

Of 843 unvaccinated adults with anti-RBD measured within two months preceding the Omicron wave. 566 (67%) completed the follow-up survey between 1/19/2022-2/7/2022. 20 reported interval COVID-19 vaccination and were excluded. The median (interquartile range, IQR) age was 48 (37-59) years, 295 (54%) were women, 453 (83%) were white, 203 (37%) reported having a test-confirmed COVID-19 diagnosis before the Omicron wave, and 328 (60%) had anti-RBD antibodies before the Omicron wave. 446 (82%) reported no regular public mask use since December 1, 2021. Participants with and without anti-RBD antibodies were similar with respect to age, sex, race, ethnicity, and mask use (Table). 35% of unvaccinated individuals without preexisting antibodies (anti-RBD<0.8 U/mL, n=218) reported test-confirmed COVID-19; an additional 12% reported suspected/unconfirmed COVID-19 during the Omicron wave. In contrast, 12% of unvaccinated individuals with preexisting antibodies (anti-RBD>0.8 U/mL, n=328) reported test-confirmed COVID-19 and an additional 15% reported suspected/unconfirmed COVID-19 during the Omicron wave. Among those with anti-RBD 0.8-1000 U/mL (n=284), 12%/16% reported confirmed/suspected COVID-19, and among those with anti-RBD≥1000 U/mL (n=44), 9%/7% reported confirmed/suspected COVID-19 (Supplementary Figure). Having antibodies was 67% effective against reporting test-confirmed COVID-19(35% vs 12% p<0.001). Among those with test-confirmed COVID-19 who answered symptom questions (n=115), those with antibodies reported shorter symptom duration than their antibody-negative counterparts (median[IQR] 3.5 [3, 5] vs. 6 [3, 8] days, p=0.013). There was a higher proportion of antibody-negative participants (vs. positive) in the COVID-19-confirmed (38% vs 24%, p=0.15), and suspected/unconfirmed groups (22% vs. 6%, p=0.06), but neither difference was statistically significant.

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

In this national longitudinal study of incident COVID-19 among unvaccinated adults during the Omicron wave, only 12% of those who entered the wave with anti-RBD antibodies reported a test-confirmed COVID-19 infection, compared to 35% of those without antibodies prior to the Omicron wave. Effectiveness of these anti-RBD antibodies, presumably derived from previous infection, in this unvaccinated population was 67%. Recently, reduced vaccine efficacy against Omicron has been described among 4x-vaccinated Israelis, and the additional protection of a 4th dose peaked four weeks post-fourth dose and waned in later weeks.[4-5] Our results add valuable information to the discussion of vaccine versus infection-derived immune protection against Omicron.[6-7] Study limitations include lack of information about direct neutralization against Omicron (though anti-RBD correlation with neutralization is described), lack of viral sequencing (though follow-up occurred when Omicron became the dominant strain in the US), self-reported COVID-19 test results, limited availability of COVID-19 testing during the follow-up period which could lead to underreporting of COVID-confirmed cases, and survivor bias.[3] In conclusion, the presence of anti-RBD antibodies in an unvaccinated healthy adult (natural immunity) was associated with 23% decreased relative risk for COVID-19 reinfection and shorted symptom duration versus those without pre-existing anti-RBD antibodies during the Omicron wave. Among people with antibodies, titer did not appear to be associated with risk of test-confirmed Omicron infection, although our sample size for those ≥1000 U/mL may have been inadequate to detect such a difference in that range. It is important to note that while disease severity for hospitalized Omicron patients was somewhat lower for Omicron versus other variants, patients hospitalized with COVID-19 remain at substantial risk of critical illness and death. [8] Our findings shed some light on COVID protection among the unvaccinated-immune.

References

135

141142

143

144

145146

149

150

151

152

153154

158

- 1. Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States. Accessed
 2/2/2022 https://covid.cdc.gov/covid-data-tracker/#vaccinations vacc-people-onedose-pop-5yr
- 2. Alejo JL, Mitchell J, Chang A, et al. Prevalence and Durability of SARS-CoV-2 Antibodies Among
 Unvaccinated US Adults by History of COVID-19. JAMA. Published online February 03, 2022.
 doi:10.1001/jama.2022.1393
 - 3. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43-50. doi:10.1126/science.abm3425
 - Rössler A, Riepler L, Bante D, Von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. New England Journal of Medicine. 2022. doi:10.1056/nejmc2119236.
- 5. Bar-On YM, Goldberg Y, Mandel M, et al.. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. New England Journal of Medicine. 2022. doi:10.1056/nejmoa2201570.
 - 6. Lauring AS, Tenforde MW, Chappell JD, et al.. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022:e069761. doi:10.1136/bmj-2021-069761.
 - 7. Accorsi EK, Britton A, Fleming-Dutra KE, et al.. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022. doi:10.1001/jama.2022.0470.
- 8. Regev-Yochay G, Gonen T, Gilboa M, et al.. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine
 against Omicron. New England Journal of Medicine. 2022;386(14):1377-1380.
 doi:10.1056/nejmc2202542.

Table. Participant demographics and clinical characteristics, by pre-Omicron anti-RBD level

160

161162

163

164165

166167

		Anti-RBD Antibody			
	Total, No. (%)	Negative	Positive	P value ^a	
No.	546	218	328		
Age, median (IQR), y	48 (37, 59)	48 (37, 62)	48 (37, 58)	0.41	
Male	251 (46%)	104 (48%)	147 (45%)	0.54	
Race ^b				0.34	
African American/Black	7 (1%)	2 (1%)	5 (2%)		
Asian	23 (4%)	10 (5%)	13 (4%)		
White	453 (83%)	187 (86%)	266 (81%)		
Other	63 (12%)	19 (9%)	44 (13%)		
Hispanic ^b	67 (12%) (n=543)	24 (11%)	43 (13%)	0.51	
Mask use since Dec 1, 2021				0.20	
Yes	96 (18%)	44 (20%)	52 (16%)		
No	446 (82%)	173 (79%)	273 (83%)		
Declined to answer	4 (1%)	1 (<1%)	3 (1%)		
Anti-RBD median (IQR)	34.6 (<0.8, 228.7)	<0.8 (<0.8, <0.8)	168 (56, 499)	< 0.001	
Prior COVID Infection					
Prior COVID confirmed	203 (37%)	2 (1%)	201 (61%)	< 0.001	
Prior COVID unconfirmed	183 (34%)	71 (33%)	112 (34%)		
No prior COVID	160 (29%)	145 (67%)	15 (5%)		
Omicron-wave-confirmed	115 (21%)	77 (35%)	38 (12%)	< 0.001	
Symptoms: severe or moderate	38 (33%)	29 (38%)	9 (24%)	0.15	
severe ^c	1 (1%)	1 (1%)	0 (0%)		
moderate ^c	37 (32%)	28 (36%)	9 (24%)		
Symptoms: mild or none	77 (67%)	48 (62%)	29 (76%)		
mild ^c	74 (64%)	45 (58%)	29 (76%)		
none ^c	3 (3%)	3 (4%)	0 (0%)		
Symptom duration median (IQR), d $^{\rm c}$	5 (3, 7)	6 (3, 8)	3.5 (3, 5)	0.01	
Omicron-wave-suspected	76 (14%)	27 (12%)	49 (15%)	< 0.001	
Symptoms: severe or moderate	9 (12%)	6 (22%)	3 (6%)	0.06	
severe ^d	0 (0%)	0 (0%)	0 (0%)		
moderate ^d	9 (12%)	6 (22%)	3 (6%)		
Symptoms: mild or none	67 (88%)	21 (77%)	46 (94%)		
mild ^d	64 (84%)	19 (70%)	45 (92%)		
none ^d	3 (4%)	2 (7%)	1 (2%)		
Symptom duration median (IQR), d ^d	4 (3, 5)	5 (3, 6)	4 (2, 5)	0.04	
Omicron-wave-none	355 (65%)	114 (52%)	241 (73%)	<0.001	

Abbreviation: RBD, receptor-binding domain.

^a Fisher exact test used for categorical variables and Wilcoxon rank-sum test for continuous variables.

^b Race and ethnicity were collected during recruitment to perform weighted random sampling among the 3 groups for antibody testing. Participants could select from African-American/Black, Asian, White, or other. Ethnicity was self-reported. Participants could select from Hispanic/Latino: yes/no.

^c Among Omicron-wave-confirmed, N=115

^d Among Omicron-wave-unconfirmed, N=76

Figure. Distribution of self-reported COVID-19 infections after December 1, 2021 among unvaccinated

US Adults, stratified by pre-Omicron wave anti-RBD antibody level.

